

RESEARCH ARTICLE

Characterization of a Novel Mouse Model of Alzheimer's Disease—Amyloid Pathology and Unique β -Amyloid Oligomer Profile

Peng Liu^{1,3*}, Jennifer B. Paulson^{1,3}, Colleen L. Forster^{2,3}, Samantha L. Shapiro^{1,3}, Karen H. Ashe^{1,3,4,5}, Kathleen R. Zahs^{1,3*}

1 Department of Neurology, University of Minnesota, Minneapolis, Minnesota, United States of America, **2** University of Minnesota Academic Health Center Biological Materials Procurement Network (BioNet), University of Minnesota, Minneapolis, Minnesota, United States of America, **3** N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, Minnesota, United States of America, **4** Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota, United States of America, **5** Geriatric Research Education and Clinical Centers, Veterans Affairs Medical Center, Minneapolis, Minnesota, United States of America

* liuxx726@umn.edu (PL); zahsx001@umn.edu (KRZ)



OPEN ACCESS

Citation: Liu P, Paulson JB, Forster CL, Shapiro SL, Ashe KH, Zahs KR (2015) Characterization of a Novel Mouse Model of Alzheimer's Disease—Amyloid Pathology and Unique β -Amyloid Oligomer Profile. PLoS ONE 10(5): e0126317. doi:10.1371/journal.pone.0126317

Academic Editor: Masuo Ohno, Nathan Kline Institute and New York University Langone Medical Center, UNITED STATES

Received: November 17, 2014

Accepted: March 31, 2015

Published: May 6, 2015

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the [Creative Commons CC0](https://creativecommons.org/licenses/by/4.0/) public domain dedication.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by the National Institute for Neurological Diseases and Stroke (NS33249) within the National Institutes of Health (<http://www.ninds.nih.gov/>) to KHA and a gift from B. Grossman to KHA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abstract

Amyloid plaques composed of β -amyloid (A β) protein are a pathological hallmark of Alzheimer's disease. We here report the generation and characterization of a novel transgenic mouse model of A β toxicity. The rTg9191 mice harbor a transgene encoding the 695 amino-acid isoform of human amyloid precursor protein (APP) with the *Swedish* and *London* mutations (APP_{NLI}) linked to familial Alzheimer's disease, under the control of a tetracycline-response element, as well as a transgene encoding the tetracycline transactivator, under the control of the promoter for calcium-calmodulin kinase II α . In these mice, APP_{NLI} is expressed at a level four-fold that of endogenous mouse APP and its expression is restricted to fore-brain regions. Transgene expression was suppressed by 87% after two months of doxycycline administration. Histologically, we showed that (1) A β plaques emerged in cerebral cortex and hippocampus as early as 8 and 10.5–12.5 months of age, respectively; (2) plaque deposition progressed in an age-dependent manner, occupying up to 19% of cortex at ~25 months of age; and (3) neuropathology—such as abnormal neuronal architecture, tau hyperphosphorylation and misfolding, and neuroinflammation—was observed in the vicinity of neuritic plaques. Biochemically, we determined total A β production at varied ages of mice, and we showed that mice produced primarily fibrillar A β assemblies recognized by conformation-selective OC antibodies, but few non-fibrillar oligomers (e.g., A β *56) detectable by A11 antibodies. Finally, we showed that expression of the tetracycline transactivator resulted in reduced brain weight and smaller dentate-gyrus size. Collectively, these data indicate that rTg9191 mice may serve as a model for studying the neurological effects of the fibrillar A β assemblies *in situ*.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Beta-amyloid ($A\beta$) plaques are one of the pathological hallmarks of Alzheimer's disease (AD). $A\beta$ plaques can typically be classified as diffuse or dense-core types based on morphology and affinity for thioflavin S or Congo red [1]. It is well established that, in the brains of AD patients and amyloid precursor protein (APP) transgenic mice, dense-core—but not diffuse—plaques are associated with varied forms of neuropathology, such as neuroinflammation, abnormal neuronal architecture, and hyperphosphorylation and misfolding of tau [2–10] (for review see [1]). However, recent studies suggest that soluble oligomeric assemblies of $A\beta$ are more likely responsible for AD pathogenesis (reviewed in [11, 12]). In AD patients or model organisms of the disease, $A\beta$ assumes multiple oligomeric forms, including but not limited to: $A\beta$ dimers, $A\beta^{*56}$, amylospheroids, and annular protofibrils [13–17]. These brain-derived oligomers have been identified based on size and composition, and each has a unique spatial and temporal expression pattern [14–20]. In addition, $A\beta$ assemblies have been characterized based on their immunoreactivity to conformation-selective antibodies—OC, which recognizes an epitope found in $A\beta$ fibrils and some soluble oligomers (“fibrillar oligomers”), and A11 which recognizes a mutually exclusive epitope found on other soluble oligomers (“non-fibrillar oligomers”) [19–21].

Understanding the neurological effects of each type of oligomer has been difficult, because numerous $A\beta$ assemblies often coexist within an individual brain. Here, we report the generation and characterization of a novel APP transgenic mouse model (rTg9191) uniquely suited to study the neurological effects of fibrillar $A\beta$ aggregates *in situ*. These mice, which express a regulatable APP transgene, develop an amyloid plaque load similar to that of AD patients, and produce fibrillar $A\beta$ assemblies but negligible amounts of non-fibrillar oligomers.

Results

Expression and suppression of APP transgene

We created a regulatable transgenic mouse line, rTg9191, modeling $A\beta$ pathology in AD. The rTg9191 mice harbor the 695 amino-acid isoform of human APP (APP_{NLI}) with the *Swedish* (K670N and M671L, numbered according to the 770-amino acid isoform of APP) and *London* (V717I) mutations that are linked to familial AD (Fig 1). Expression of APP_{NLI} is driven by an interaction between the *tetO* promoter and the tetracycline-controlled transactivator (tTA), whose expression is driven by a calcium-calmodulin kinase II α (CaMKII α) promoter. Transgene expression can be suppressed by doxycycline (DOX)-mediated disruption of the tTA-*tetO* interaction (Fig 2A). Western blot analyses of the membrane-enriched fraction of brain protein extracts showed that the rTg9191 line expresses APP_{NLI} at a level four times that of endogenous mouse APP (Fig 2B and 2C). Additionally, we found that the level of APP_{NLI} remains constant with age and is two-thirds the transgenic APP level in Tg2576 mice (S1A and S1B Fig).

Administration of DOX to mice for 2 months resulted in an 87% reduction in the level of APP_{NLI} expression (Fig 2D and 2E).

Regional expression pattern of APP transgene

The expression of APP_{NLI} in various brain regions was analyzed using LN27 and 6E10, two antibodies that recognize the N-terminus and $A\beta$ region of human APP, respectively. For both antibodies, APP_{NLI} expression was observed in cerebral cortex, hippocampus, and olfactory bulb—but not in cerebellum; in addition, the level of expression was qualitatively similar in the cerebral cortex and hippocampus, but was lower in the olfactory bulb (Fig 3). This regional expression pattern of the transgene in rTg9191 mice is consistent with that seen in the rTg4510 and rTg3696AB lines, which share the same binary tet-off induction system as the rTg9191 line [22, 23].




Fig 1. The APP_{NLI} responder transgene construct. The 695 amino acid-long amyloid precursor protein cDNA harboring the *Swedish* mutation (APP_{NL}695) was inserted into the *Xho*I site of MoPrP.Xho fragment, which was further excised at two *Xba*I sites. The resulting fragment of prnp.APP_{NL} was cloned into the unique *Xba*I site in the inducible expression vector pTRE. The *London* mutation (V717I) was further introduced into the pTRE.prnp.APP_{NL} plasmid using site-directed mutagenesis.

doi:10.1371/journal.pone.0126317.g001

Beta-secretase-mediated APP processing

Beta-secretase-mediated digestion of APP to release C-terminal fragments (CTF β) is the first step in amyloidogenic A β production. This 99 amino acid-long APP fragment is associated with multiple neurological ill-effects, including neuroinflammation and neurodegeneration, disruption of neuronal ionic homeostasis, and learning and memory impairments (reviewed in [24]). We measured the levels of CTF β at different ages in rTg9191 mice and found an age-dependent increase in the level of CTF β (S1A and S1C Fig), despite the fact that the level of APP_{NLI} remained constant with age. We also compared the levels of CTF β in rTg9191 mice to the level found in Tg2576 mice. At 21 months of age, rTg9191 mice generate a level of CTF β (relative to transgenic APP) equivalent to that of age-matched Tg2576 mice (S1A and S1C Fig), as might be expected, since both lines harbor the *Swedish* mutation.

Age-dependent progression of A β plaques

We tracked the onset and accumulation of A β plaques in cerebral cortex and hippocampus of rTg9191 mice from 2 to 26 months of age. Plaques were visualized using four antibodies: 6E10 (recognizes an N-terminal region of A β), 4G8 (recognizes the mid- region of A β), 139-5 (A β 40




Fig 2. Expression and suppression of transgenic APP in rTg9191 mice. (A) Bigenic activator-reponder system. rTg9191 mice employ a bigenic system in which a calcium-calmodulin kinase II α (CaMKII α) promoter drives constitutive expression of the tetracycline-controlled transactivator (*tTA*) gene, and a responder transgene for human APP₆₉₅ containing the *Swedish* and *London* mutations (*APP_{NLI}*) is under control of the tetracycline response element (*tetO*). Regulatable expression of the APP transgene in the rTg9191 line is under the control of doxycycline (DOX). In the absence of DOX, tTA binds the *tetO* promoter and *APP_{NLI}* is expressed; in the presence of DOX, the tTA-*tetO* interaction is blocked, and expression of *APP_{NLI}* is suppressed. (B-C) Expression of *APP_{NLI}*. (B) Representative immunoblot probed with monoclonal antibody 22C11, which recognizes both mouse and human APP; numbers above the blot show amounts of protein loaded in each lane. (C) Quantification. Thirty-five μ g of protein from brains of 2-month-old non-transgenic (neg) mice is required to produce the same APP signal as 7 μ g of protein from age-matched rTg9191 littermates, indicating that transgenic mice have 5 times more APP (mouse + human) than non-transgenic mice. Therefore, rTg9191 mice express 4 times more *APP_{NLI}* relative to mouse APP. DLU, densitometric light unit. (D-E)

Suppression of APP_{NLI} expression. (D) Representative immunoblot using monoclonal antibody 6E10, which recognizes human A β 1–16; 10 μ g of protein was loaded in each lane. Alpha-tubulin served as the loading control. 8M^{on} and 10M^{on}: 8- and 10-month-old rTg9191 mice without DOX treatment; 8-10M^{off}: 10-month-old rTg9191 mice, treated with DOX from 8 to 10 months of age. (E) Quantification. Administration of DOX (200 ppm in chow) to rTg9191 mice decreased levels of APP_{NLI} by 87%. *** $p < 0.0001$, one-way ANOVA followed by Fisher's *post hoc* analysis.

doi:10.1371/journal.pone.0126317.g002

end-specific antibody), and 1-11-3 (A β 42 end-specific antibody). For all four antibodies, we found that plaques emerged first in the cerebral cortex, as early as 8 months of age, and then appeared in the hippocampus, between 10.5–12.5 months of age; plaque accumulation age-dependently progressed in both cortex and hippocampus (Fig 4A–4E). While 6E10, 4G8, and 1-11-3 detected both dense-core and diffuse plaque (Fig 4B, 4C and 4E; S2A, S2B, and S2D Fig), 139–5 seemed to recognize only dense-core plaques (Fig 4D; S2C Fig). We quantified burdens of 4G8-immunoreactive plaques in both cerebral cortex and hippocampus of mice between 10.5 and 24.7 months of age. These plaques included both the dense-core and diffuse types. Comparable plaque loads in cortex and hippocampus were found at each of the ages examined.




Fig 3. Regional expression pattern of the APP transgene in rTg9191 mice. The regional pattern of APP_{NLI} expression in four distinct anatomical structures (cerebral cortex (Ctx.), hippocampus (Hpp.), olfactory bulb (Olf.), and cerebellum (Cbm.)) of brain was analyzed using mouse monoclonal antibody LN27, which specifically recognizes human APP, and 6E10. The APP transgene was expressed in cerebral cortex and hippocampus with a minor portion in olfactory bulb; however, no expression was observed in cerebellum. No immunoreactivity using these human-specific antibodies was seen in non-transgenic littermates (neg). Alpha-tubulin served as the loading control. Representative blots show the APP_{NLI} expression pattern of female mice, and similar results were found in male mice.

doi:10.1371/journal.pone.0126317.g003




Fig 4. Age-related A β plaque progression in rTg9191 mice. (A) A representative sagittal section of brain. Black rectangles indicate the regions of cerebral cortex and hippocampal formation in which A β plaques are shown in (B-E). (B-E) Representative photomicrographs showing age-dependent progression of A β plaques in female mice, visualized using 6E10 (B); 4G8, directed against a mid-region of A β (C); 139-5, an A β_{x-40} -specific antibody (D); and 1-11-3, an A β_{x-42} -specific antibody (E). Upper panels, cerebral cortex; lower panels, hippocampus. Scale bars: 100 μ m (upper panels), 200 μ m (lower panels). TTA, mice expressing only the tetracycline transactivator. (F) Quantification of 4G8-immunoreactive A β plaque load at various ages.

doi:10.1371/journal.pone.0126317.g004

At 24.7 months of age, plaques loads reached 19% and 17%, respectively, for cortex and hippocampus (Fig 4F). We also revealed dense-core plaques of aged rTg9191 mice using thioflavin S. At 24.7 months of age, plaque loads were 0.41% and 0.37% for cortex and hippocampus, respectively (S2E and S2F Fig).

Age-related A β production

We determined the levels of A β 38, A β 40, and A β 42 proteins in brain parenchyma from rTg9191 mice at young (4 months), middle (12 months), and old (21 and 24 months) ages using an enzyme-linked immunosorbent assay (ELISA). The levels of A β proteins were separately measured in the water-soluble (Fig 5A), detergent-soluble (Fig 5B), and detergent-insoluble (Fig 5C) fractions. Overall, we observed an age-dependent increase in the production of A β 38, A β 40, and A β 42 in all three fractions—the one exception being that the level of A β 40 in the water-soluble fraction of 21-month-old mice was slightly lower than that of 12-month-old mice. This relative reduction in A β 40 might be caused by the coincidental formation of A β 40-comprising dense-core plaques (Fig 4D). Of particular interest is that in the water-soluble fraction, levels of A β 40 were higher than A β 42 prior to plaque formation (i.e., at 4 and 12 months of age), but, in aged mice (i.e., 21 and 24 months of age), this relationship between A β 40 and A β 42 was reversed (Fig 5A); in addition, in 21- and 24-month-old mice with high plaque loads, levels of A β 42 decreased from water-soluble to detergent-soluble and insoluble fractions, whereas levels of A β 40 increased (Fig 5A–5C). These findings, together with observations concerning age-related plaque progression in mice, indicate that a majority (> 90%) of A β 40 builds the dense cores of plaques, and that A β 42 accounts for the main A β components of diffuse plaques and loosely core-associated oligomers, which remain water-soluble following protein extraction.

Age-related production of soluble A β oligomeric assemblies

We next investigated age-dependent production of soluble A β oligomeric assemblies in brains of rTg9191 mice. We asked whether rTg9191 mice produce A β dimers and A β *56, the two brain-derived oligomeric assemblies that have been linked to memory deficits and memory-related electrophysiological dysfunction [14, 15]. Under denaturing experimental conditions, we analyzed these oligomers from brain extracts of young (4 months of age), mid-aged (12 months of age), and old (21, 24, and 26 months of age) mice. A β dimers were not detected at 12 months of age; however from 21–24 months of age, dimer levels increased steeply and then plateaued (Fig 6A and 6B). In contrast, A β *56 was not detectable at any age in rTg9191 mice. A β *56 similarly was absent from memory-intact TgArc6 mice, but was prominent in memory-impaired 4-month-old hAPP-J20 mice [25] included for comparison (Fig 6C and 6D). Therefore, rTg9191 mice produce A β dimers in an age-dependent manner, but do not generate detectable levels of A β *56.

We also employed dot blotting to characterize A β oligomers in the water-soluble fraction of brain extracts, under non-denaturing conditions. We used OC antibodies to examine and compare levels of soluble fibrillar oligomers in rTg9191 mice at various ages, aged Tg2576 mice, and AD patients (Fig 7A and 7B). We found that rTg9191 mice exhibited an age-dependent increase in OC immunoreactivity. At 4 months of age, OC immunoreactivity of rTg9191 mice was no more than that of non-transgenic controls. When rTg9191 mice reached 21 months of age, the level of OC immunoreactivity matched that of AD patients; at 24 months of age, OC immunoreactivity further increased and was comparable to that of 21-month-old Tg2576 mice. To confirm that the OC immunoreactivity arose from A β oligomers, we performed immunodepletion using an array of antibodies directed against various epitopes on A β . Immunodepleting A β from brains of rTg9191, Tg2576 mice, and AD patients decreased OC immunoreactivity to a level comparable to that of the non-transgenic brains, indicating that OC-immunoreactive signals come from soluble A β oligomers.

In parallel, we used A11 antibodies to detect soluble non-fibrillar oligomers in rTg9191 and Tg2576 mice, as well as in AD patients (Fig 7C and 7D). We found that levels of A11




Fig 5. Age-related production of A β proteins in water-soluble, detergent-soluble, and detergent-insoluble fractions of brain extracts from rTg9191 mice. The levels of total A β 38, A β 40, and A β 42 proteins in water-soluble (A), detergent-soluble (B) and detergent-insoluble (C) fractions of brain extracts of rTg9191 mice at 4, 12, 21, and 24 months of age were measured using ELISA.

doi:10.1371/journal.pone.0126317.g005

immunoreactivity in rTg9191 mice at all ages were comparable to levels in non-transgenic littermates. In contrast, aged Tg2576 mice and AD patients exhibited higher A11 immunoreactivities. Immunodepletion of A β decreased A11 immunoreactivity in brains of both Tg2576 mice and AD patients, which have previously been shown to contain the A11-positive oligomer A β *56 [15, 18].

In summary, our results show that rTg9191 mice produce OC-immunoreactive fibrillar A β oligomers in an age-dependent manner, but have few, if any, non-fibrillar A β oligomers as recognized by A11 antibodies.




Fig 6. rTg9191 mice produce A β dimers in an age-dependent manner, but lack A β^*56 . (A-B) Production of A β dimers. (A) A representative immunoblot (upper panel) shows levels of A β dimers in young, mid-age, and old mice; α -tubulin served as the loading control (lower panel). (B) Quantification. rTg9191 mice exhibit an age-dependent progression in levels of A β dimers. # $p < 0.05$, *** $p < 0.0001$ (compared to 26M), one-way ANOVA, followed by Fisher's *post hoc* analysis. (C-D) rTg9191 mice lack A β^*56 . (C) Representative immunoblot shows levels of A β^*56 in transgenic mouse lines rTg9191, TgArc6, and hAPP-J20. Although a faint band at ~56kDa was seen occasionally in extracts from rTg9191 mice, the intensity of this band was comparable to that seen in some samples from non-transgenic mice. As monoclonal antibody 6E10 recognizes human, but not mouse A β , this faint band represents non-specific background noise, and not a true A β signal. (D) Quantification. The intensity of the ~56kDa band in rTg9191 mice (4, 12, 21, 24 and 26M of age) is comparable to that of non-transgenic littermates (neg, 26M) and TgArc6 (4M), but is significantly lower than that of hAPP-J20 (4M). *** $p < 0.0001$, each group compared to hAPP-J20, one-way ANOVA, followed by Fisher's *post hoc* analysis. Neg, non-transgenic littermates of rTg9191 mice; pos, mice that express APP transgenes. Samples from both genders were loaded onto the representative blots, aligning in the order of left to right for (A): F, M, F, F, M, M, F, M, F, F (M, male; F, female), and for (C): F, F, M, M, F, M, F, M, F, M, F, F, M, F, F, M, F, F.

doi:10.1371/journal.pone.0126317.g006

TTA expression is associated with low brain weights and small dentate gyri

A previous study showed that expression of the tetracycline transactivator (TTA) during development resulted in neuron loss in the hippocampus of transgenic mice [26]. We investigated the effects of TTA expression on hippocampal size and brain weight. For this, we first compared body and brain weights of rTg9191 mice with their littermates carrying only the TTA




Fig 8. TTA expression results in reduced forebrain weight and dentate-gyrus size. (A) Weights of rTg9191 mice (APP/TTA), littermates harboring only the activator gene (TTA), only the responder gene (APP), and neither gene (non-Tg). There were no genotype-related differences in body weight in young and mid-aged mice. Aged rTg9191 mice, however, had lower body weights compared to their littermates. (B) rTg9191 mice and TTA littermates have lower forebrain weights than their APP and non-Tg littermates at all ages studied. The numbers of mice examined are shown for each genotype. # $p < 0.05$, * $p < 0.01$, ** $p < 0.001$, *** $p < 0.0001$, two-way ANOVA followed by Fisher's *post hoc* analysis. The percentage of female mice in the genotype of APP/TTA, TTA, APP, and non-Tg is 50%, 38%, 67%, and 55%, respectively for the 2–6 month-old; 51%, 35%, 48%, and 50%, respectively for the 13–17 month-old; 46%, 61%, 47%, and 51%, respectively for the 24–27 month-old. Chi square/Fisher exact tests showed no significant difference in gender distribution between genotypes. (C–F) Representative photomicrographs showing hematoxylin and eosin staining of the hippocampal regions of 16.5-month-old rTg9191 mice and their age-matched littermates. Sections at ~ 1.20 mm lateral from the midline were used. The sizes of dentate gyri of rTg9191 (F) and TTA (E) mice are decreased compared to those of APP (D) and non-Tg (C) littermates. Scale bar: 200 μ m, applies to C–F. Representative photomicrographs show hippocampus hematoxylin and eosin staining of female mice, and similar results were observed in male mice.

doi:10.1371/journal.pone.0126317.g008

transgene, only the APP_{NLI} transgene, or no transgenes. We grouped mice into three categories: young (2–6 months of age), middle-aged (13–17 months of age), and old (24–27 months of age) to increase the size of each group and enhance the power of statistical analysis. No genotype-related alteration in body weight was found in young and middle-aged mice, while old rTg9191 had lower body weights than the other three genotypes (Fig 8A). Forebrain weights of the TTA-expressing mice were significantly lower than mice expressing no TTA (Fig 8B).

To understand the structural basis of the reduction in brain weight induced by TTA expression, we examined the size of the hippocampus. Consistent with the previous report [26], we found that at middle age (~ 17 months of age), TTA-expressing mice (rTg9191 and TTA) had smaller dentate gyri and thinner granule cell layers, compared to non-transgenic littermates and mice harboring only the APP_{NLI} transgene (Fig 8C–8F). No genotype-related differences were noticeable in the CA1 and CA3 areas.

Plaque-associated neuropathology

We asked whether rTg9191 mice exhibit neuropathology in the vicinity of plaques, as has been described in the brains of other APP transgenic mice and in AD patients [5, 7, 10, 27]. We found




Fig 9. Plaque-associated neuroinflammation and abnormal neuronal architecture in rTg9191 mice. (A-I) rTg9191 mice show reactive gliosis in the vicinity of dense-core plaques. Brain sections from rTg9191 mice at 24 months of age (B, E, H), their age-matched non-transgenic littermates (A, D, G), and age-matched Tg2576 mice (C, F, I) were stained with antibodies directed against the astroglial marker S100 β (A-C), a monoclonal antibody directed against the microglial marker ionized calcium-binding adaptor molecule 1 (Iba1) (D-F), and an antibody directed against the astrocytic marker glial fibrillary acidic protein (GFAP) (G-I). Astrocytes and activated microglial cells and reside near dense-core plaques visualized using Congo red (pink). Scale bar in I, 25 μ m, applies to A-I. (J-K) rTg9191 mice exhibited abnormal neuronal architecture around plaques. Thioflavin S (green) was used to visualize plaques and monoclonal antibody SMI-312 was used to visualize axons (red). (J) No plaques were detected in age-matched non-transgenic littermates of rTg9191 mice, and neuronal morphologies were normal. (K) Plaques are surrounded by swollen, dystrophic axons (arrowheads) and curly, distorted axonal processes (arrows) in brains of rTg9191 mice. Scale bar in K, 50 μ m, applies to J and K. Representative photomicrographs show neuroinflammation and neuronal architecture of female mice, and similar results were found in male mice.

doi:10.1371/journal.pone.0126317.g009

that, similar to Tg2576 mice, gliosis in rTg9191 was associated with Congo red-positive, dense-core plaques (Fig 9A–9I). In addition, we found aggravated axonal curvature and swollen, dystrophic neurites surrounding thioflavin S-positive plaques in rTg9191 mice (Fig 9J and 9K), resembling findings in AD and transgenic mouse brains [5, 10]. We next examined plaque-associated tau pathology using an array of well-characterized antibodies directed against hyperphosphorylated and conformationally altered tau forms (Fig 10). Immunoreactive profiles surrounded dense-core plaques in rTg9191 mice, as also shown in Tg2576 mice (this study, [28]).

To rule out the possibility that plaque-associated neuropathology was induced by the expression of tetracycline transactivator (TTA), we examined these pathological features in mice expressing only TTA. We showed that similar to the non-transgenic, no gliosis, neuronal dystrophy or tau hyper-phosphorylation was observed in brains of rTg9191 littermates expressing only TTA (S3 and S4 Figs).




Fig 10. Plaque-associated tau pathology in rTg9191 mice. Brain sections from rTg9191 mice of 24 months of age (B, F, J, N, R, V, Z), their age-matched non-transgenic littermates (A, E, I, M, Q, U, Y), 23-month-old Tg2576 mice (C, G, K, O, S, W, AA) and 15-month-old rTg4510 mice (D, H, L, P, T, X, AB) were stained with a variety of antibodies directed against pathological conformation- and phosphorylation-dependent epitopes of tau: AT8 (A-D), CP13 (E-H), PG5 (I-L), PHF-1 (M-P), Alz50 (Q-T), MC1 (U-X) and TG-3 (Y-AB). Representative photomicrographs showed that hyperphosphorylated and/or misfolded tau proteins accumulated (brown puncta) around dense-core plaques visualized using Congo red (pink). Neuronal staining (brown) in rTg4510 mice served as positive control. Scale bars: 20 μ m. Images in the same row have the same magnification. Representative photomicrographs show tau pathology of female mice, and similar results were found in male mice.

doi:10.1371/journal.pone.0126317.g010

Discussion

In this report, we describe the generation and the biochemical and immunohistochemical characteristics of a regulatable APP transgenic mouse model—rTg9191.

We used sequence-specific antibodies to determine the temporal profiles of individual A β oligomers detected under denaturing conditions, and found that levels of A β dimers increased in an age-dependent manner, but that A β *56 was absent from rTg9191 mice. In addition, we used conformation-selective antibodies to detect A β assemblies under non-denaturing conditions. Studies using conformation-selective antibodies indicate that there are at least two

structurally distinct classes of amyloid oligomers: fibrillar assemblies and non-fibrillar assemblies, recognized by the polyclonal antibodies OC and A11, respectively [29]. The OC antibodies preferentially recognize the in-register parallel β -sheet structure (Liu et al. manuscript submitted) that full-length A β adopts in neuritic plaques of AD brain [30]. The exact conformation that is detected by A11 antibodies is currently unresolved, but there is evidence that A11 recognizes an out-of-register, anti-parallel β -sheet structure [31, 32]. A unique feature of rTg9191 mice is that they produce primarily fibrillar A β assemblies, and have few, if any, non-fibrillar oligomers that are immunoreactive to A11.

We showed here that an age-dependent increase in OC-immunoreactive A β assemblies paralleled the age-dependent increase in dimer levels. This observation begs the question of whether A β dimers, detected under denaturing conditions on Western blots, are related to OC-immunoreactive fibrillar oligomers, detected under native conditions using dot blots. Additional biochemical experiments suggest that A β dimers might represent breakdown products of larger OC-positive oligomers. When water-soluble brain extracts of aged rTg9191 mice were fractionated using size exclusion chromatography (SEC), a majority of A β proteins were eluted in two peaks with apparent molecular weights of 670–2,000 kDa and ~150 kDa. Upon Western blot analysis, both SEC peaks were shown to contain A β dimers, indicating that either (a) these dimers may arise from disassembled high-molecular-weight OC-immunoreactive assemblies, or (b) that free dimers do exist in the brain, but are eluted anomalously because of their possible non-globular structure (Liu et al. manuscript submitted).

The generation of a transgenic mouse line that specifically generates fibrillar A β aggregates was fortuitous. The particular A β oligomer profile generated in each line of APP transgenic mouse likely results from multiple factors, including genetic background, level of transgene expression, and Alzheimer's disease-linked mutation(s) in the transgene that influence the A β 42/A β 40 ratio. APP processing, A β metabolism and amyloid deposition have been shown to vary with genetic background, even when levels of APP expression remain constant [33]. Studies comparing hAPP-J20, TgArc6, and TgArc48 mice suggest that both the levels of transgene expression and the propensity for aggregation of the resulting A peptides are also critical factors governing the levels of globular oligomers, such as A β *56 [25]. hAPP-J20 mice carry an APP mini-gene with *Swedish* ($K_{670}M_{671} \rightarrow N_{670}L_{671}$) and *Indiana* ($V_{717} \rightarrow F_{717}$) mutations, while TgArc6 and TgArc48 mice carry this same transgene with the addition of the *Arctic* ($E_{693} \rightarrow G_{693}$) mutation; all three lines are in the same C57Bl/6 genetic background. A comparison of TgArc48 and TgArc6 mice suggests that APP levels influence A β oligomer formation: although these two lines carry the same APP transgene in the same genetic background, TgArc48 mice express six times more APP and three times more A β *56 than do TgArc6 mice. Further, comparing TgArc mice to hAPP-J20 mice suggests that the fibrillogenicity of the A β peptides also influences the oligomer profile: the lines bearing the *Arctic* mutation generate approximately half the amount of A β *56, normalized to APP levels, as does the hAPP-J20 line. Cheng and colleagues hypothesized that accelerating the formation of fibrils, by inclusion of the *Arctic* mutation, may lower the globular A β species either by diverting monomers in a limiting pool away from the formation of globular assemblies, or by sequestering the globular assemblies directly into fibrils [25].

The APP transgene in rTg9191 mice is similar to that in hAPP-J20 mice in that it contains the *Swedish* mutation that increases production of all forms of A [34, 35], as well as an additional mutation (the *Indiana* mutation in hAPP-J20 and the *London* mutation ($V_{717} \rightarrow I_{717}$) in rTg9191) that shifts APP processing towards A β 42 [36] (reviewed in [37]). However, hAPP-J20 mice generate A β *56, while rTg9191 mice do not. At this time, we can only speculate about which factors account for the different oligomer profiles observed in these two lines. Not only do rTg9191 and hAPP-J20 mice differ in genetic background, but also in the construction

of the APP transgene. As described here, rTg9191 mice are bi-genic, with the CaMKII α promoter driving expression of the tetracycline transactivator in excitatory neurons of the fore-brain [38], while the responder consists of cDNA encoding the 695-amino acid isoform of APP. By contrast, hAPP-J20 mice carry an APP mini-gene driven by the platelet-derived growth factor promoter [39]. Notably, the two lines differ in the amount of A β produced, in an age-dependent manner. At younger ages, steady-state levels of soluble A β 40 and A β 42 are comparable in hAPP-J20 and rTg9191 mice, but in mice greater than a year of age, levels of A β peptides in rTg9191 mice greatly exceed those measured in hAPP-J20 mice (compare values shown in Fig 5 of this report to Fig 2 of [40]).

In addition to examining plaque-associated neuropathology, we also evaluated the relevance of our novel model to AD and several other mouse models of AD by quantifying and comparing dense-core plaque load in brain parenchyma. We observed that the density of neuritic plaques in rTg9191 mice was comparable to that in AD brains, whereas in some other mouse model systems, such as *Tg(APP^{swe},PSEN1^{dE9})85* [25] and *Tg(5xFAD)6799* [41], plaque loads were substantially greater than in AD (Liu et al. manuscript submitted).

In summary, we have developed rTg9191 mice, a novel regulatable APP transgenic model that specifically produces fibrillar A β assemblies. This unique feature allows studying the neurological effects of fibrillar A β assemblies *in situ*, including the effects of such assemblies on cognition and plaque-associated neuropathology. Further, the regulatable property of the model allows temporal modulation of APP expression and A β production. This feature enables studies of the interactions of A β with age-related factors and, of particular clinical relevance, studies of the persistence of A β -triggered pathology following reductions in A β production.

Materials and Methods

Generation of rTg9191 mice

Our methods for generating rTg9191 mice utilized a binary system of responder and activator transgenes. Mice expressing a transgene (CKII-tTA) [38] encoding a tetracycline-controlled transactivator under control of the calcium-calmodulin-dependent kinase II α promoter were derived from mice that were a generous gift from Dr. Eric Kandel at Columbia University, New York, NY. These mice were successively backcrossed at least five times onto a 129S6 background strain. To construct the responder APP transgene, APP_{NL}695 flanked by *SalI* linkers was cloned into the unique *XhoI* site of MoPrP.Xho to generate prnp.APP_{NL}. Next, the *XbaI* fragment of prnp.APP_{NL}, including partial sequences of prnp introns 1 and 2, along with exons 2–3, and the APP_{NL} open reading frame, was cloned into the unique *XbaI* site in the inducible expression vector pTRE (Clontech, Inc., Palo Alto, CA), resulting in the plasmid pTRE.prnp.APP_{NL}. The *London* mutation (V717I) was introduced into the pTRE.prnp.APP_{NL} plasmid using a site-directed mutagenesis kit (Stratagene, Santa Clara, CA), using the following primers: 5' –GCG ACA GTG ATC ATC ACC TTG GTG ATG CTG–3' and 5' –CAG CAT CAC CAA GGT GAT GAT GAT CAC TGT CGC–3'. The resulting plasmid (pTRE.prnp.APP_{NLI}) was transformed into XL-1 blue competent cells (Stratagene) that were plated on Lucia Broth plates with ampicillin. Clones were selected and plasmid DNA was purified using a miniprep kit (Qiagen, Valencia, CA) and sequenced for accuracy. The pTRE.prnp.APP_{NLI} plasmid was digested using *AsnI*, fractionated, and purified using a gel extraction kit (Qiagen) and dialysis. The concentration of the purified fragment containing the modified APP transgene was adjusted to 2 μ g/mL, and was introduced by microinjection into the pronuclei of donor FVB/N embryos using standard techniques. Mice carrying the responder APP transgene (APP_{NLI}) were maintained in the FVB/N strain, and identified by polymerase chain reaction (PCR) using the following primers: 5' –AAG CGG CCA AAG CCT GGA GGG TGG AAC A–3' and 5' –GTT GAG

CCT GTT GAT GCC CG-3'. The APP_{NLI} responders were subsequently mated to the activator TgCKII-tTA line, and pups positive for both transgenes were screened by PCR using the primer pairs 5' -GAT TAA CAG CGC ATT AGA GCT G-3' and 5' -GCA TAT GAT CAA TTC AAG GCC GAT AAG-3' for the activator transgene, and 5' -AAG CGG CCA AAG CCT GGA GGG TGG AAC A-3' and 5' -GTT GAG CCT GTT GAT GCC CG-3' for the responder transgene.

Animals

All studies involving mice were conducted in full accordance with the guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Minnesota (approval # 1202A09927). Animals were conventionally housed in plastic boxes with contact bedding and Nestlets. Mice were group-housed (maximum 4 per cage), except in the case of aggressive males, who were singly-housed. Animals were maintained on a 12-hour ON: 12-hour OFF light cycle, given *ad libitum* access to food and water, and monitored daily for evidence of injury or overtly aggressive behavior. For the study of transgene suppression, mice were administered doxycycline (200 ppm of chow) in their chow. At the ages enumerated below, mice were deeply anesthetized with isoflurane (absence of toe-pinch and corneal-blink reflexes) and decapitated for harvest of brains. All efforts were made to minimize suffering. Litters were sacrificed at pre-determined ages, and mice from each litter were randomly allocated to the different biochemical and histological studies.

Human tissue

De-identified brain tissue samples were obtained from 6 elderly individuals enrolled in the Religious Orders Study, which was approved by the Institutional Review Board of Rush University Medical Center, Chicago, IL. Participants enroll without dementia and consent to annual clinical evaluation and sign an Anatomical Gift Act for organ donation. (Regarding this particular issue, please also see the following statement from Dr. David A. Bennett, principal investigator of the Religious Orders Study and director of the Rush Alzheimer's Disease Center—"Participants enroll without dementia and consent to annual clinical evaluation and sign an Anatomical Gift Act for organ donation. As this is a study until death, they are asked if they wish to designate someone with the power to remove them from the study at a later date should they become decisionally compromised in the future.") These individuals were clinically and pathologically diagnosed with Alzheimer's disease later. Proteins were extracted from the inferior temporal gyrus (Brodmann Area 20) using an adapted protocol of Shankar et al. [14]. Protein extraction and biochemical analyses were performed as described below.

As stated above, these samples were procured from ROS at the Rush Alzheimer's Disease Center, Chicago, Illinois. URL of the Rush Alzheimer's Disease Center—<http://www.rush.edu>. URL of the ROS at the Rush Alzheimer's Disease Center—<http://www.rush.edu/services-treatments/alzheimers-disease-center/religious-orders-study>.

The specific samples used in this study have been described in a previous publication—Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, et al. (2013) Brain amyloid-beta oligomers in ageing and Alzheimer's disease. *Brain* 136: 1383–1398.

Preparation of synthetic A β oligomers and fibrils

A11-immunoreactive A β oligomers were prepared *in vitro* as previously described [19]. Briefly, 50 μ g of A β was dissolved in 20 μ L of hexafluoroisopropanol (HFIP) for 15 min at room temperature. The resulting A β solution was added to 180 μ L of ddH₂O in a siliconized Eppendorf tube. After 15 min incubation at room temperature, the samples were centrifuged for 15 min at

14,000 g and the supernatant fraction (pH 2.8–3.5) was transferred to a new siliconized tube, and the HFIP was evaporated off. The samples were then stirred using a Teflon coated micro stir bar for 24–48 hr at 22°C. OC-immunoreactive, soluble A β fibrillar aggregates were a kind gift from Dr. Robert Tycko, National Institutes of Health, Bethesda, MD.

Protein extraction

To better characterize protein of interest, we used three different extraction protocols to isolate proteins according to their solubility (three-step and two-step) and cellular compartmentalization (four-step).

A three-step protocol [14] was used to extract brain proteins that were used: 1) to measure levels of total A β in rTg9191 mice (Fig 5), 2) to measure levels of water-soluble A β dimers in rTg9191 mice (Fig 6A and 6B), and 3) to quantify soluble oligomers that are immunoreactive to OC or A11 antibodies in rTg9191 and Tg2576 mice and AD patients (Fig 7).

To prepare the water-soluble fraction, tissue specimens were weighed, transferred to 4 volumes (1 gm per 4 mL) of ice-cold buffer A (25 mM Tris-HCl, pH 7.4; 140 mM NaCl; 3 mM KCl; 0.1 mM phenylmethylsulfonyl fluoride; 0.2 mM 1,10-phenanthroline monohydrate; protease inhibitor cocktail (P8340, Sigma-Aldrich, St. Louis, MO); and phosphatase inhibitor cocktails (P2850 and P5726, Sigma-Aldrich)) and homogenized using a Dounce homogenizer. The resulting material was centrifuged for 90 min (16,100 g; 4°C); the supernatant was then depleted of endogenous immunoglobulins [42] and stored at -20°C until further use. The pellets were reserved for the extraction of detergent-soluble proteins.

To extract detergent-soluble proteins, the pellets obtained above were transferred to 4 volumes of ice-cold buffer B (25 mM Tris-HCl, pH 7.4; 140 mM NaCl; 3 mM KCl; 1% (v/v) Triton-X-100; 0.1 mM phenylmethylsulfonyl fluoride; 0.2 mM 1,10-phenanthroline monohydrate; protease inhibitor cocktail (P8340, Sigma-Aldrich); and phosphatase inhibitor cocktails (P2850 and P5726, Sigma-Aldrich)) and homogenized using a Dounce homogenizer. The resulting material was centrifuged for 90 min (16,100 g; 4°C); the supernatant was depleted of endogenous immunoglobulins and stored at -20°C until further use. The pellets were reserved for the extraction of detergent-insoluble proteins.

To extract insoluble proteins, the pellets obtained above were transferred to 40 μ L of 70% formic acid and homogenized by repeatedly pipetting and vigorously shaking at room temperature for 30 min. The acidic pH of the resulting material was neutralized using 800 μ L of 1 M Tris-base solution (no pH adjustment, pH ~10.6) and centrifuged for 90 min (16,100 g; 4°C). The supernatant was collected and stored at -20°C until further use.

A four-step fractionation protocol [15, 43] was employed 1) to determine the expression level of human APP (Fig 2B and 2C), 2) to determine the degree of DOX-mediated suppression of APP expression (Fig 2D and 2E), and 3) to investigate the regional pattern of APP expression (Fig 3).

Each hemi-forebrain was mechanically homogenized in 500 μ L of Extraction Buffer 1 (50 mM Tris-HCl, pH 7.6; 150 mM NaCl; 2 mM EDTA; 0.1% (w/v) SDS; and 0.01% (v/v) NP-40, with the protease and phosphatase inhibitors mentioned above). Supernatants were collected after centrifugation (800 g; 10 min, 4°C) to obtain soluble, extracellular-enriched proteins. The resulting pellets were homogenized in 500 μ L Extraction Buffer 2 (50 mM Tris-HCl, pH 7.6; 150 mM NaCl; and 0.1% (v/v) Triton-X-100, with protease and phosphatase inhibitors) followed by centrifugation (16,100 g; 90 min, 4°C). Supernatants were collected to obtain cytoplasmic proteins. The resulting pellets were gently agitated (15 min, 4°C) in 1 mL Extraction Buffer 3 (50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 1 mM EGTA; 3% (w/v) SDS; 1% (w/v) deoxycholate; and 0.5% (v/v) Triton-X-100, and protease and phosphatase inhibitors); subsequent

centrifugation (16,100 g; 90 min, 4°C) yielded a supernatant enriched in membrane-associated proteins and a pellet containing detergent-insoluble proteins. The three detergent-soluble fractions were then depleted of endogenous immunoglobulins. Detergent-insoluble pellets were incubated with 40 μ L of 70% formic acid, mechanically dissociated, gently agitated, and neutralized with 800 μ L of 1 M Tris-base solution. Samples were centrifuged (16,100 g; 90 min, 4°C) and the supernatants were collected and concentrated to ~350–400 μ L/sample using a vacuum concentrator (Eppendorf Vacufuge 5301, room temperature, ~2 hr). Protein extracts were stored at -20°C until further use.

Finally, material obtained from a two-step brain protein extraction protocol [14] was used 1) to measure levels of A β *56 in rTg9191, TgArc6, and hAPP-J20 mice (Fig 6C and 6D), and 2) to determine levels of CTF β in rTg9191 and Tg2576 mice (S1 Fig). Forebrains were mechanically homogenized in 500 μ L of extraction buffer (50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 1 mM EGTA; 3% (w/v) SDS; 0.5% (v/v) Triton-X-100; 1% (w/v) deoxycholate; and protease and phosphatase inhibitors described above). Homogenates were gently agitated at 4°C for 1 hr, and then centrifuged for 90 min (16,100 g; 4°C). The resulting supernatant was depleted of endogenous immunoglobulins and stored at -20°C until further use. Pellets were extracted using 40 μ L of 70% formic acid and then neutralized with 400 μ L of 1 M Tris-base solution. Samples were then centrifuged (16,100 g; 90 min, 4°C); supernatants were collected and stored at -20°C until further use.

Protein concentrations of brain extracts were determined using a BCA protein assay kit (23225, Thermo Scientific, Rockford, IL) according to the manufacturer's instructions.

Immunoblot

Western blotting. Western blotting was performed using the protocol of Liu et al. [42].

Proteins were denatured by heating under reducing conditions. Tricine loading buffer (450 mM Tris-HCl, pH 8.0; 24% (v/v) glycerol; 8% (w/v) SDS; 0.01% (w/v) Coomassie Brilliant Blue; 0.1% (v/v) Phenol Red; 5% (v/v) β -mercaptoethanol) was added to each sample (1:3, v/v, buffer:sample), and the samples were heated with agitation at 95°C for 5 min. The denatured samples were loaded onto pre-cast 10–20% SDS-polyacrylamide Tris-Tricine gels (345–0067, Bio-Rad, Hercules, CA) and electrophoretically separated at room temperature at constant voltage (80 V).

The separated proteins were then transferred to nitrocellulose membranes (162–0112, Bio-Rad) under low temperature conditions (transfer performed at 4°C, 0.4 A constant current, 4 hr). Membranes were then transferred to 50 mL of PBS (prepared by dissolving one pellet of phosphate buffered saline (P4417, Sigma-Aldrich) into 200 mL of ddH₂O), and epitopes were retrieved by boiling the membranes twice for 10 sec each time, with a 4 min cooling period after each episode of boiling. Non-specific binding sites were blocked by incubating the membranes on an orbital shaker for 1–3.5 hr at room temperature in blocking buffer (10 mM Tris-HCl, pH 7.4; 200 mM NaCl; 0.1% (v/v) Tween-20; 33% (v/v) casein blocking buffer (C7594, Sigma-Aldrich); 0.05% (w/v) cold water fish skin gelatin (G7041, Sigma-Aldrich); 5% (w/v) bovine serum albumin (BSA) (A3803, Sigma-Aldrich)). Primary antibodies were then added directly to the blocking buffer as follows: mouse monoclonal 22C11 (MAB348, Millipore, Billerica, MA; directed against amino acids 66–81 of APP), 1:2,000; mouse monoclonal 4G8 (SIG-39220, Covance, Princeton, NJ; directed against amino acids 17–24 of A β), 1:10,000; mouse monoclonal 6E10 (SIG-39320, Covance; directed against amino acids 1–16 of human A β), 1:2,500; biotinylated 6E10 (SIG-39340, Covance), 1:2,500; mouse monoclonal LN27 (SIG-39188, Covance; directed against an epitope within the first 200 amino acids of human APP), 1:2,500; mouse monoclonal anti- α -tubulin (T5168, Sigma-Aldrich), 1:200,000. Membranes

were incubated overnight at 4°C on an orbital shaker. Following primary antibody incubation, membranes were rinsed once briefly with TBST wash buffer (10 mM Tris-HCl, pH 7.4; 200 mM NaCl; 0.1% (v/v) Tween-20) at room temperature, and then an additional five times for 5 min each on the orbital shaker. Membranes were then incubated for 1 hr at room temperature with secondary antibody (for Figs 2B, 2D, 3 and 6A lower panel and 6C lower panel, horseradish peroxidase (HRP)-conjugated goat-anti-mouse IgG (31437, Thermo Scientific), diluted 1:200,000 in TBST wash buffer; for Fig 6A upper panel, biotin-conjugated goat-anti-mouse IgG (31805, Thermo Scientific), diluted 1:60,000 in blocking buffer; gently agitated on the orbital shaker). When biotin-conjugated 6E10 was used (Fig 6C upper panel), secondary antibody incubation was skipped. Following secondary-antibody incubation, membranes were washed in TBST as after primary-antibody incubation. Membranes that had been incubated with biotin-conjugated secondary antibodies were then incubated at room temperature with HRP-conjugated NeutrAvidin (A2664, Invitrogen, Carlsbad, CA; diluted 1:5,000 in TBST wash buffer) for 7–8 min, with agitation (orbital shaker), and then rinsed with TBST as above. These membranes, as well as the membranes that had been incubated with HRP-conjugated secondary antibodies, were then developed using a chemiluminescence reagent (SuperSignal West Pico Chemiluminescent Substrate, 34080, Thermo Scientific; 4 min, room temperature, orbital shaker). Chemiluminescence was detected using Kodak Scientific Imaging film X-OMAT Blue XB (1776699, Perkin-Elmer Life Sciences Inc., Boston, MA) processed in a Konica medical film processor (Model SRX-101A, Konica Medical Imaging Inc., Wayne, NJ). For each blot, a series of exposures, ranging from 1 sec to 5 min, was used to ensure that bands of interest fell within the linear range of detection. Intensities of immunoreactive bands were quantified densitometrically using Optiquant (Packard Cyclone, Perkin-Elmer Life Sciences Inc.).

After being probed with anti-APP or anti-A β antibodies, the same blots were chemically stripped using Restore PLUS Western Blot Stripping Buffer (46430, Thermo Scientific) at room temperature for 1 hr. The membranes were then re-probed with anti- α -tubulin to examine the levels of total protein loaded onto the membrane according to the protocol described above.

The numbers of samples used were: 1) to determine the expression level of transgenic APP (Fig 2B and 2C): rTg9191 mice at 2 months of age, $n = 3$ (1 male and 2 females); age-matched non-transgenic littermates, $n = 3$ (1 male and 2 females); 2) to determine the degree of DOX-mediated suppression of the APP transgene (Fig 2D and 2E): rTg9191 mice at 8 months of age, $n = 3$ (2 males and 1 female); at 10 months of age, $n = 3$ (2 males and 1 female); at 10 months of age, with DOX treatment between 8–10 months of age, $n = 3$ (2 males and 1 female); non-transgenic littermates at 8 months of age, $n = 3$ (2 males and 1 female); 3) to investigate the regional expression pattern of transgenic APP (Fig 3): rTg9191 mice at 12 months of age, $n = 2$ (1 male and 1 female); age-matched non-transgenic littermates, $n = 2$ (1 male and 1 female); 4) to measure levels of A β dimers (Fig 6A and 6B): rTg9191 mice at 4 months of age, $n = 4$ (2 males and 2 females); at 12 months of age, $n = 5$ (2 males and 3 females); at 21 months of age, $n = 3$ (1 male and 2 females); at 24 months of age, $n = 3$ (1 male and 2 females); at 26 months of age, $n = 6$ (3 males and 3 females); non-transgenic littermates at 26 months of age, $n = 3$ (1 male and 2 females); and 5) to measure levels of A β *56 (Fig 6C and 6D): rTg9191 mice at 4 months of age, $n = 3$ (1 male and 2 females); at 12 months of age, $n = 5$ (2 males and 3 females); at 21 months of age, $n = 5$ (2 males and 3 females); at 24 months of age, $n = 6$ (3 males and 3 females); at 26 months of age, $n = 8$ (4 males and 4 females); non-transgenic littermates at 26 months of age, $n = 3$ (1 male and 2 females); TgArc6 mice at 4 months of age, $n = 5$ (2 males and 3 females); hAPP-J20 mice at 4 months of age, $n = 5$ (2 males and 3 females). Each experiment was repeated three times.

Dot blotting. For dot blots probed with OC antibodies, 0.5 μ g of water-soluble protein from brain extracts and 2 ng of synthetic soluble A β fibrillar aggregates were spotted onto nitrocellulose

membranes. Membranes were first rinsed three times with Tris-buffered saline (TBS) at room temperature for 5 min each, and then incubated in 10% (w/v) non-fat milk in Tris-buffered saline with 0.01% (v/v) Tween-20 (TBS-T) at room temperature for 1 hr. Membranes were then washed five times with TBS-T for 4 min each on an orbital shaker, and then incubated overnight with OC antibodies (AB2286, Millipore; diluted 1:50,000 in TBS-T with 5% (w/v) BSA) at 4°C. Membranes were then washed five times with TBS-T at room temperature for 5 min each, and then incubated for 1 hr with secondary antibody solution at room temperature HRP-conjugated goat-anti-rabbit IgG (31463, Thermo Scientific; diluted 1:200,000 in TBS-T).

A similar protocol was applied to dot blots probed with A11 antibodies except that: 1) 1 μ g of water-soluble protein extracts and 1 μ g of synthetic A β oligomers were dotted, 2) membranes were blocked with 5% (w/v) BSA in TBS, 3) A11 antibodies (a kind gift from Dr. Rakez Kaye, University of Texas, Galveston, TX) were diluted 1:2,000 in blocking buffer, 4) membranes were washed with TBS, and 5) secondary antibody was applied to membranes in TBS.

To confirm that the immunoreactivities of conformation-selective antibodies came from A β assemblies, we performed immunodepletion: Brain extracts and synthetic A β aggregates were also incubated overnight with a combination of four anti-A β antibodies (i.e., 6E10, 4G8; and rabbit monoclonals 139-5 (SIG-39166, Covance) and 1-11-3 (SIG-39169, Covance)—two C-terminal end-specific antibodies directed against A β 40 and A β 42, respectively) at 4°C. Antibody-A β complexes and any remaining free antibodies were removed by three rounds of precipitation using Protein G Sepharose 4 FF resin (17-0618-01, GE Healthcare, Piscataway, NJ). Immunodepleted materials of the same portion as the original samples were dotted onto the same membrane to make a direct comparison to the untreated samples.

Blot development and densitometry-based quantitative analysis were similarly performed as described in **Western blotting**.

After being probed with conformation-sensitive antibodies, the same blots were chemically stripped using Restore PLUS Western Blot Stripping Buffer at room temperature for 1 hr. The membranes were then re-probed with anti- α -tubulin, according to the standard Western blot protocol described above, to confirm equal loading of protein across samples.

The numbers of samples examined in dot blots are: rTg9191 mice at 4 months of age, $n = 3$ (1 male and 2 females); at 12 months of age, $n = 3$ (1 male and 2 females); at 21 months of age, $n = 3$ (1 male and 2 females); at 24 months of age, $n = 3$ (1 male and 2 females); non-transgenic littermates of rTg9191 mice at 4 months of age, $n = 3$ (1 male and 2 females); at 24-months of age, $n = 3$ (1 male and 2 females); Tg2576 mice at 21 months of age, $n = 3$ (1 male and 2 females); age-matched non-transgenic littermates of Tg2576, $n = 3$ (1 male and 2 females); AD patients, $n = 3$ (2 males and 1 female). Each experiment was repeated three times.

Enzyme-linked immunosorbent assay (ELISA)

Total A β 38, A β 40, and A β 42 protein levels in the water-soluble (TBS), detergent-soluble (TBS-TX) and insoluble (FA) fractions of brain extracts of rTg9191 mice at young (4-month-old, $n = 3$ (1 male and 2 females)), middle (12-month-old, $n = 5$ (2 males and 3 females)), and old (21-month-old, $n = 3$ (1 male and 2 females); and 24-month-old, $n = 5$ (2 males and 3 females)) ages were measured using a multi-plex ELISA for A β 38, A β 40, and A β 42 (N45148A-1, Meso Scale Discovery, Rockville, MD) following the manufacturer's instructions. In this assay, C-terminal end-specific antibodies against A β 38, A β 40, and A β 42 are used as immunocapture reagents, and mouse monoclonal antibody 6E10 directed against amino acids 1–16 of human A β is used as the detection antibody. Signals were detected and quantified using a Meso Sector S 600 plate reader (MesoScale Discovery). Samples were analyzed in duplicate, and the mean values are reported.

Histology and immunohistochemistry

The rTg9191 mice were aged and sacrificed at two-month intervals from 2–26 months of age. Mice were weighed immediately before they were anesthetized using isoflurane and killed by decapitation. After mice were sacrificed, brains were immediately dissected, and weights of whole brains and right forebrains were recorded. Left hemispheres were immersion-fixed in 10% formalin for 24–48 hr, then embedded in paraffin. Brains were serially sectioned in the parasagittal plane using a Leica RM2255—Fully Motorized Rotary Microtome (Leica Microsystems, Buffalo Grove, IL) and mounted onto CapGap slides (Fisher Scientific, Pittsburgh, PA).

Amyloid plaques. To investigate the age-dependent progression of A β plaques, eight transgenic mice (APP/TTA) (four males and four females), two littermates expressing only the TTA activator (TTA) (one male and one female), two harboring only the APP responder gene (APP) (one male and one female) and two non-transgenics (non-Tg) (one male and one female) were analyzed. Three 5 μ m-thick parasagittal sections from each animal, at ~0.84, 1.20, and 1.56 mm lateral from the midline [44], were prepared. Selected sections were deparaffinized and rehydrated according to standard protocols. For epitope retrieval, mounted slides were pretreated in 70% formic acid at room temperature for 5 min. Tissue sections were subsequently blocked with Background Sniper (Universal) blocking reagent (BS966 MM, Biocare Medical, Concord, CA) at room temperature for 1 hr, then incubated with monoclonal antibodies 6E10 (1:8,000), 4G8 (1:3,000), 139–5 (1:500), and 1-11-3 (1:400) at 4°C overnight. A β immunostained profiles were visualized using diaminobenzidine chromagen. Hematoxylin and eosin counterstaining was used to provide cytological detail.

Quantification of amyloid burden. Amyloid plaques, immunostained with 4G8, were viewed with an Axio Imager upright microscope (Carl Zeiss Microimaging GmbH, Göttingen, Germany) equipped with an AxioCam MRc color digital camera. Stereology-based quantification of amyloid burden was carried out using Stereo Investigator 9 software (MBF Bioscience, Chicago, IL). The entire cerebral cortex and hippocampus were separately sampled with the counting frame size 250 μ m \times 250 μ m for cortex and 100 μ m \times 100 μ m for hippocampus. The sum of the area of all amyloid plaques was divided by the total area of cerebral cortex or hippocampus to obtain the amyloid burden. Experimenters performing quantification of amyloid burden were blind to age and genotype of mice.

Glial markers and hyperphosphorylated tau. To investigate gliosis and tau pathology, five rTg9191 mice (24 months of age, 2 males and 3 females), four age-matched non-transgenic littermates (2 males and 2 females), two age-matched non-transgenic littermates expressing only TTA (1 male and 1 female), three Tg2576 (23 months of age, 1 male and 2 females) mice, and one rTg4510 (15 months of age, female) mouse were used. Formalin-fixed, paraffin-embedded (FFPE) hemispheres were sectioned at 10 μ m in the parasagittal plane. Sections were de-paraffinized and rehydrated using standard methods, then incubated in 1 \times Reveal Decloaker buffer (RV 1000 M, Biocare Medical) in a steamer for 30 min at 95–98°C for antigen retrieval. Endogenous peroxidase activity was quenched in 3% (v/v) hydrogen peroxide solution (Peroxidized, Biocare Medical) for 10 min. Tissue sections were subsequently blocked with serum-free blocking solution (Rodent Block M (RBM961 MM, Biocare Medical)) at room temperature for 15 min. Blocking solution was removed and slides were incubated in primary antibodies diluted in 10% blocking solution/90% TBS (v/v) for 1 hr at room temperature. The following primary antibodies were used: 1) to probe astrocytes and microglial cells: rabbit polyclonals anti-S100 (1:40,000) (Z0311, DAKO, Carpinteria, CA), anti-GFAP (1:30,000) (Z0334, DAKO) and anti-Iba1 (1:2,000) (019–19741, Wako Chemicals, Richmond, VA); and 2) to probe hyperphosphorylated and misfolded tau: mouse monoclonals AT8 (1:400) (MN1020B, Thermo Scientific), Alz50 (1:100), CP13 (1:4,000), MCI

(1:800), PG5 (1:200), PHF-1 (1:1,500) and TG-3 (1:100) (the latter 6 antibodies are kind gifts from Dr. P. Davies, Albert Einstein College of Medicine, New York, NY). Immunoreactivities were visualized using diaminobenzidine chromagen. The sections were then counterstained in 1% (w/v) Congo red (C6277, Sigma-Aldrich) aqueous solution for 1 hr at room temperature to visualize dense-core plaques. Finally, hematoxylin and eosin staining was used to provide cytological detail.

Axonal pathology. To study dense-core plaques and axonal pathology, FFPE hemispheres from three 24-month-old rTg9191 mice (1 male and 2 females) and two non-transgenic littermates (1 male and 1 female) were sectioned at 16 μ m in the parasagittal plane. To visualize axon structure, every 15th section (240 μ m interval) was rehydrated; subjected to antigen retrieval (treated with 1 \times Reveal Decloaker buffer in a Black & Decker steamer for 35 min with a 20-min cool down); blocked (Rodent Block M, room temperature for 1 hr); then incubated with monoclonal antibody SMI-312 (SMI-312R, Covance), directed against axonal neurofilaments (diluted 1:2,000 in 10% (v/v) Background Sniper (Universal) blocking reagent, 4°C, overnight) followed by Alexa Fluor 555-conjugated donkey-anti-mouse (A31570, Invitrogen; diluted 1:2,000 in 10% Background Sniper (Universal) blocking reagent). To reveal dense-core plaques, sections immunostained with SMI-312 were counterstained with freshly prepared 1% (w/v) thioflavin-S (T1892, Sigma-Aldrich) aqueous solution at room temperature for 5 min followed by differentiation using 70% ethanol.

For all immunostaining, sections were also exposed to secondary antibodies only. In such cases, no positive labeling was observed.

Hematoxylin and eosin stain. To visualize brain structure, eight APP/TTA (four males and four females), two TTA (one male and one female), two APP (one male and one female) and two non-Tg (one male and one female) mice were analyzed. Three 5 μ m-thick sections from each animal, at ~0.84, 1.20, and 1.56 mm lateral from midline, were prepared. Hematoxylin and eosin staining was performed on selected sections according to standard protocols.

Statistics

Statistics were performed using StatView Version 5.0.1 (SAS Institute Inc., Cary, NC). Data are expressed as mean \pm SEM.

Supporting Information

S1 Fig. Beta-secretase-mediated APP processing in rTg9191 mice. (A) Representative blots show levels of C-terminal fragment (CTF β) generated by β -secretase cleavage of APP. The production of CTF β was studied at four ages (12, 21, 24 and 26 months); in addition, levels of CTF β from mice (26M*) treated with DOX for 2 months starting at 24 months of age were also examined. Membrane-enriched fraction of brain extracts was immucaptured with 6E10; CTF β (upper panels) and full-length APP (fl-APP) (middle panels, short exposure) were revealed by anti-APP antibodies (directed against an epitope within C-terminus of APP). Immunoblots of immunoglobulin heavy chain (IgG_H) (lower panels) show that equal amounts of capture antibody were used to react with each sample. For each blot, two 20 month-old Tg2576 mice were used as internal controls for comparing levels of proteins between different blots. No Ab.: no capture antibody was included in immunoreactions; No. Extr.: no protein extracts were included in immunoreactions; No Extr. or Ab.: only matrix was included. Asterisk (*) between fl-APP and CTF β in upper panels: non-specific signals. (B-C) Quantification of fl-APP (B) and CTF β (normalized to fl-APP) (C) of rTg9191 and Tg2576 mice. Genders of mice whose brain extracts were used in the Western blots, aligning in the order of left to right, are: N/A, F(24-month-old), N/A, M, F, M, F, M, F, F, M, F, F; M, F, F, M, F, M, F, F,

F, M, M, F; M, F, M, F, M, F, F, M, F, M, F; M, F, M, F, M, F, F, M, M, M, F (N/A, no extracts applied; M, male; F, female).

(TIF)

S2 Fig. Amyloid plaque pathology of rTg9191 mice. (A–D) Representative high magnification photomicrographs show details of dense-core (arrowheads) and diffuse (arrows) plaques recognized by 6E10 (A), 4G8 (B), 139–5 (anti- $A\beta_{x-40}$) (C) and 1-11-3 (anti- $A\beta_{x-42}$) (D). (E–F) Representative photomicrographs show dense-core plaques stained by thioflavin S in cerebral cortex (E) and hippocampus (F). Scale bars: 50 μ m (A–D), 200 μ m (E–F). All photomicrographs represent brain sections of female mice.

(TIF)

S3 Fig. Neuroinflammation and abnormal neuronal architecture in rTg9191 mice and littermates expressing only tetracycline transactivator (TTA). (A–D) TTA mice showed no apparent reactive gliosis. Brain sections from TTA (A,C) and rTg9191 mice (B,D) at 24 months of age were stained with a monoclonal antibody directed against the microglial marker ionized calcium-binding adaptor molecule 1 (Iba1) (A,B), and an antibody directed against the astrocytic marker glial fibrillary acidic protein (GFAP) (C,D). Congo red was then applied to stain plaques. Representative photomicrographs show staining of the molecular layer of dentate gyrus. No plaques were detected in TTA mice and no activated microglial cells or astrocytes were overtly observed. Scale bars in B and D, 25 μ m, applies to A–D. (E) TTA mice exhibited no dystrophic neurites. Brain sections were stained with monoclonal antibody SMI-312 to visualize axons (red) and counterstained using thioflavin S. Scale bar, 50 μ m. Compare image in (E) to Fig 9J and 9K. All photomicrographs are of brain sections of female mice.

(TIF)

S4 Fig. Tau pathology in rTg9191 and TTA mice. Brain sections of TTA (A,C,E,G,I,K,M) and rTg9191 mice (B,D,F,H,J,L,N) stained with antibodies directed against pathological conformation- and phosphorylation-dependent epitopes of tau: AT8 (A,B), CP13 (C,D), PG5 (E, F), PHF-1 (G,H), Alz50 (I,J), MC1 (K,L) and TG-3 (M,N) and counterstained with Congo red. Representative photomicrographs show staining of the molecular layer of the dentate gyrus. No hyperphosphorylated and/or misfolded tau was observed in TTA mice. Scale bars: 20 μ m, applies to all images. All photomicrographs are of brain sections of female mice.

(TIF)

S1 Text. Supplementary Materials and Methods.

(DOC)

Acknowledgments

We thank Dr. Sylvain Lesné and Mathew Sherman for provide water-soluble AD brain extracts.

Author Contributions

Conceived and designed the experiments: PL KHA KRZ. Performed the experiments: PL JBP CLF SLS. Analyzed the data: PL KHA KRZ. Contributed reagents/materials/analysis tools: CLF KHA. Wrote the paper: PL KRZ.

References

1. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. *Cold Spring Harb Perspect Med*. 2011; 1(1):a006189. Epub 2012/01/10. doi: [10.1101/cshperspect.a006189](https://doi.org/10.1101/cshperspect.a006189) a006189 [pii]. PMID: [22229116](https://pubmed.ncbi.nlm.nih.gov/22229116/).
2. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. *J Neuroimmunol*. 1989; 24(3):173–82. Epub 1989/10/01. PMID: [2808689](https://pubmed.ncbi.nlm.nih.gov/2808689/).
3. Pike CJ, Cummings BJ, Cotman CW. Early association of reactive astrocytes with senile plaques in Alzheimer's disease. *Exp Neurol*. 1995; 132(2):172–9. Epub 1995/04/01. PMID: [7789457](https://pubmed.ncbi.nlm.nih.gov/7789457/).
4. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. *Neurobiol Aging*. 2003; 24(2):321–31. Epub 2002/12/25. S0197458002000908 [pii]. PMID: [12498966](https://pubmed.ncbi.nlm.nih.gov/12498966/).
5. Urbanc B, Cruz L, Le R, Sanders J, Ashe KH, Duff K, et al. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. *Proc Natl Acad Sci U S A*. 2002; 99(22):13990–5. PMID: [12374847](https://pubmed.ncbi.nlm.nih.gov/12374847/).
6. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, et al. Neuron loss in APP transgenic mice. *Nature*. 1998; 395(6704):755–6. PMID: [0009796810](https://pubmed.ncbi.nlm.nih.gov/0009796810/).
7. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. *J Neuropathol Exp Neurol*. 1997; 56(9):965–73. PMID: [0009291938](https://pubmed.ncbi.nlm.nih.gov/0009291938/).
8. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. *J Neurosci*. 1997; 17(18):7053–9. PMID: [0009278541](https://pubmed.ncbi.nlm.nih.gov/0009278541/).
9. Su JH, Cummings BJ, Cotman CW. Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. *Brain Res*. 1996; 739(1–2):79–87. Epub 1996/11/11. S0006-8993(96)00811-6 [pii]. PMID: [8955927](https://pubmed.ncbi.nlm.nih.gov/8955927/).
10. Knowles RB, Wyart C, Buldyrev SV, Cruz L, Urbanc B, Hasselmo ME, et al. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. *Proc Natl Acad Sci U S A*. 1999; 96(9):5274–9. Epub 1999/04/29. PMID: [10220456](https://pubmed.ncbi.nlm.nih.gov/10220456/).
11. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol*. 2007; 8(2):101–12. Epub 2007/01/25. nrm2101 [pii] 10.1038/nrm2101. PMID: [17245412](https://pubmed.ncbi.nlm.nih.gov/17245412/).
12. Larson ME, Lesne SE. Soluble Abeta oligomer production and toxicity. *J Neurochem*. 2012; 120 Suppl 1(2011):125–39. Epub 2011/11/30. doi: [10.1111/j.1471-4159.2011.07478.x](https://doi.org/10.1111/j.1471-4159.2011.07478.x) PMID: [22121920](https://pubmed.ncbi.nlm.nih.gov/22121920/).
13. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, et al. Morphology and toxicity of Abeta-(1–42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. *J Biol Chem*. 1996; 271(34):20631–5. PMID: [8702810](https://pubmed.ncbi.nlm.nih.gov/8702810/).
14. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat Med*. 2008; 14(8):837–42. Epub 2008/06/24. nm1782 [pii]. doi: [10.1038/nm1782](https://doi.org/10.1038/nm1782) PMID: [18568035](https://pubmed.ncbi.nlm.nih.gov/18568035/).
15. Lesne S, Koh MT, Kotilinek L, Kaye R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. *Nature*. 2006; 440(7082):352–7. PMID: [16541076](https://pubmed.ncbi.nlm.nih.gov/16541076/).
16. Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, et al. Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. *J Biol Chem*. 2009; 284(47):32895–905. Epub 2009/09/18. M109.000208 [pii]. doi: [10.1074/jbc.M109.000208](https://doi.org/10.1074/jbc.M109.000208) PMID: [19759000](https://pubmed.ncbi.nlm.nih.gov/19759000/).
17. Lasagna-Reeves CA, Glabe CG, Kaye R. Amyloid-beta annular protofibrils evade fibrillar fate in Alzheimer disease brain. *J Biol Chem*. 2011; 286(25):22122–30. Epub 2011/04/22. M111.236257 [pii]. doi: [10.1074/jbc.M111.236257](https://doi.org/10.1074/jbc.M111.236257) PMID: [21507938](https://pubmed.ncbi.nlm.nih.gov/21507938/).
18. Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, et al. Brain amyloid-beta oligomers in ageing and Alzheimer's disease. *Brain*. 2013; 136(Pt 5):1383–98. doi: [10.1093/brain/awt062](https://doi.org/10.1093/brain/awt062) PMID: [23576130](https://pubmed.ncbi.nlm.nih.gov/23576130/); PubMed Central PMCID: PMC3634198.
19. Kaye R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science*. 2003; 300(5618):486–9. PMID: [12702875](https://pubmed.ncbi.nlm.nih.gov/12702875/).
20. Kaye R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. *Mol Neurodegener*. 2007; 2:18. Epub 2007/09/28. 1750-1326-2-18 [pii]. doi: [10.1186/1750-1326-2-18](https://doi.org/10.1186/1750-1326-2-18) PMID: [17897471](https://pubmed.ncbi.nlm.nih.gov/17897471/).

21. Wu JW, Breydo L, Isas JM, Lee J, Kuznetsov YG, Langen R, et al. Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. *J Biol Chem.* 2010; 285(9):6071–9. Epub 2009/12/19. M109.069542 [pii]. doi: [10.1074/jbc.M109.069542](https://doi.org/10.1074/jbc.M109.069542) PMID: [20018889](https://pubmed.ncbi.nlm.nih.gov/20018889/); PubMed Central PMCID: [PMC2825401](https://pubmed.ncbi.nlm.nih.gov/PMC2825401/).
22. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). *J Neurosci.* 2005; 25(46):10637–47. PMID: [16291936](https://pubmed.ncbi.nlm.nih.gov/16291936/).
23. Paulson JB, Ramsden M, Forster C, Sherman MA, McGowan E, Ashe KH. Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease. *Am J Pathol.* 2008; 173(3):762–72. Epub 2008/08/02. [ajpath.2008.080175](https://pubmed.ncbi.nlm.nih.gov/ajpath.2008.080175) [pii]. doi: [10.2353/ajpath.2008.080175](https://doi.org/10.2353/ajpath.2008.080175) PMID: [18669616](https://pubmed.ncbi.nlm.nih.gov/18669616/).
24. Suh YH, Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. *Pharmacol Rev.* 2002; 54(3):469–525. Epub 2002/09/12. PMID: [12223532](https://pubmed.ncbi.nlm.nih.gov/12223532/).
25. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. *J Biol Chem.* 2007; 282(33):23818–28. Epub 2007/06/06. M701078200 [pii]. doi: [10.1074/jbc.M701078200](https://doi.org/10.1074/jbc.M701078200) PMID: [17548355](https://pubmed.ncbi.nlm.nih.gov/17548355/).
26. Han HJ, Allen CC, Buchovecky CM, Yetman MJ, Born HA, Marin MA, et al. Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator. *J Neurosci.* 2012; 32(31):10574–86. Epub 2012/08/03. doi: [10.1523/JNEUROSCI.0893-12.2012](https://doi.org/10.1523/JNEUROSCI.0893-12.2012) 32/31/10574 [pii]. PMID: [22855807](https://pubmed.ncbi.nlm.nih.gov/22855807/); PubMed Central PMCID: [PMC3431916](https://pubmed.ncbi.nlm.nih.gov/PMC3431916/).
27. D'Amore JD, Kajdasz ST, McLellan ME, Bacskai BJ, Stern EA, Hyman BT. In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. *J Neuropathol Exp Neurol.* 2003; 62(2):137–45. Epub 2003/02/13. PMID: [12578223](https://pubmed.ncbi.nlm.nih.gov/12578223/).
28. Yang F, Ueda K, Chen P, Ashe KH, Cole GM. Plaque-associated alpha-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein. *Brain Res.* 2000; 853(2):381–3. PMID: [0010640638](https://pubmed.ncbi.nlm.nih.gov/0010640638/).
29. Kaye R, Glabe CG. Conformation-dependent anti-amyloid oligomer antibodies. *Methods Enzymol.* 2006; 413:326–44. Epub 2006/10/19. S0076-6879(06)13017-7 [pii]. doi: [10.1016/S0076-6879\(06\)13017-7](https://doi.org/10.1016/S0076-6879(06)13017-7) PMID: [17046404](https://pubmed.ncbi.nlm.nih.gov/17046404/).
30. Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R. Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. *Cell.* 2013; 154(6):1257–68. Epub 2013/09/17. S0092-8674(13)01029-5 [pii]. doi: [10.1016/j.cell.2013.08.035](https://doi.org/10.1016/j.cell.2013.08.035) PMID: [24034249](https://pubmed.ncbi.nlm.nih.gov/24034249/); PubMed Central PMCID: [PMC3814033](https://pubmed.ncbi.nlm.nih.gov/PMC3814033/).
31. Laganowsky A, Liu C, Sawaya MR, Whitelegge JP, Park J, Zhao M, et al. Atomic view of a toxic amyloid small oligomer. *Science.* 2012; 335(6073):1228–31. doi: [10.1126/science.1213151](https://doi.org/10.1126/science.1213151) PMID: [22403391](https://pubmed.ncbi.nlm.nih.gov/22403391/); PubMed Central PMCID: [PMC3959867](https://pubmed.ncbi.nlm.nih.gov/PMC3959867/).
32. Liu C, Zhao M, Jiang L, Cheng PN, Park J, Sawaya MR, et al. Out-of-register beta-sheets suggest a pathway to toxic amyloid aggregates. *Proc Natl Acad Sci U S A.* 2012; 109(51):20913–8. doi: [10.1073/pnas.1218792109](https://doi.org/10.1073/pnas.1218792109) PMID: [23213214](https://pubmed.ncbi.nlm.nih.gov/23213214/); PubMed Central PMCID: [PMC3529048](https://pubmed.ncbi.nlm.nih.gov/PMC3529048/).
33. Lehman EJ, Kulnane LS, Gao Y, Petriello MC, Pimpis KM, Younkin L, et al. Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. *Hum Mol Genet.* 2003; 12(22):2949–56. doi: [10.1093/hmg/ddg322](https://doi.org/10.1093/hmg/ddg322) PMID: [14506131](https://pubmed.ncbi.nlm.nih.gov/14506131/).
34. Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. *Science.* 1993; 259(5094):514–6. PMID: [8424174](https://pubmed.ncbi.nlm.nih.gov/8424174/).
35. Citron M, Oltsdorf T, Haass C, McConlogue L, Hung AY, Seubert P, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. *Nature.* 1992; 360(6405):672–4. PMID: [1465129](https://pubmed.ncbi.nlm.nih.gov/1465129/).
36. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr., Eckman C, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. *Science.* 1994; 264(5163):1336–40. PMID: [8191290](https://pubmed.ncbi.nlm.nih.gov/8191290/).
37. Sinha S, Lieberburg I. Cellular mechanisms of beta-amyloid production and secretion. *Proc Natl Acad Sci U S A.* 1999; 96(20):11049–53. PMID: [0010500121](https://pubmed.ncbi.nlm.nih.gov/0010500121/).
38. Mayford M, Bach ME, Huang Y-Y, Wang L, Hawkins RD, Kandel ER. Control of memory formation through regulated expression of a CaMKII transgene. *Science.* 1996; 274(6 December):1678–83. PMID: [8939850](https://pubmed.ncbi.nlm.nih.gov/8939850/)

39. Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L. Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. *J Biol Chem.* 1995; 270(47):28257–67. PMID: [0007499323](#).
40. Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, Masliah E, et al. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. *Neurobiol Dis.* 2009; 36(2):293–302. Epub 2009/08/08. S0969-9961(09)00200-9 [pii]. doi: [10.1016/j.nbd.2009.07.021](#) PMID: [19660551](#).
41. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. *Biomol Eng.* 2001; 17(6):157–65. Epub 2001/05/05. S1389034401000673 [pii]. PMID: [11337275](#).
42. Liu P, Kemper LJ, Wang J, Zahs KR, Ashe KH, Pasinetti GM. Grape seed polyphenolic extract specifically decreases abeta*56 in the brains of Tg2576 mice. *J Alzheimers Dis.* 2011; 26(4):657–66. Epub 2011/07/12. 6H333J71J4221417 [pii]. doi: [10.3233/JAD-2011-110383](#) PMID: [21743132](#).
43. Sherman MA, Lesne SE. Detecting abeta*56 oligomers in brain tissues. *Methods Mol Biol.* 2011; 670:45–56. Epub 2010/10/23. doi: [10.1007/978-1-60761-744-0_4](#) PMID: [20967582](#).
44. Franklin KB, Paxinos G. *Mouse brain in stereotaxic coordinates.* 1997.